Open AccessNoninfectious, Severe Cryoglobulinemic Vasculitis with Renal Involvement – Safety and Efficacy of Long-Term Treatment with Rituximab
Author(s) -
Ksymena Leśniak,
Aleksandra Rymarz,
Arkadiusz Lubas,
Stanisław Niemczyk
Publication year - 2021
Publication title -
international journal of nephrology and renovascular disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 27
ISSN - 1178-7058
DOI - 10.2147/ijnrd.s315388
Subject(s) - medicine , rituximab , cryoglobulinemia , cryoglobulins , adverse effect , vasculitis , gastroenterology , immunology , disease , antibody , lymphoma , hepatitis c virus , virus
The management of nonviral cryoglobulinemic vasculitis (CV) has not been established yet. Randomized control trials are challenging to perform because of the rarity of the disease. The most promising biological therapy is rituximab (RTX), an anti-CD 20 monoclonal antibody. The aim of the study was to assess rituximab treatment's safety and effectiveness in patients with severe noninfectious cryoglobulinemic vasculitis.